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Introduction
Type 1 (T1D) and type 2 diabetes (T2D) are characterized by uncon-
trolled hyperglycemia associated with the progressive decrease in 
insulin. Glucagon, insulin’s counterregulatory hormone, plays a 
major role in maintaining glucose homeostasis by promoting glu-
cose production via hepatic glycogenolysis and gluconeogenesis. 
Glucagon levels are elevated in insulin-resistant/nondiabetic T1D 
and T2D patients, leading to enhanced hepatic glucose output and 
thereby exacerbating hyperglycemia (1–3). On the contrary and 
much less understood is the failure of α cells to secrete glucagon in 
response to hypoglycemia. This presents a major limiting factor for 
optimal glucose control in T1D diabetes or advanced T2D patients 
(4–6). Thus, a better understanding of the molecular mechanisms 
governing glucagon levels could have major implications in under-
standing abnormal responses to hypoglycemia in diabetes and pro-
vide novel avenues for diabetes management.
Mice with loss of the insulin receptor in α cells have increased 
fed glucagon levels, suggesting that insulin signaling mediates the 
suppression of glucagon secretion in the fed state (7). In addition, 
mice with pancreatic deletion of the insulin receptor substrate 2 
(IRS2) exhibit decreased α cell mass and lower glucagon protein 
and RNA levels, implicating IRS signaling in the control of α cell 
mass and glucagon expression (8). Insulin inhibits glucagon gene 
transcription and secretion and promotes α cell proliferation by 
activation of IRS2/PI3K/Akt signaling (9, 10). α Cell proliferation 
is reduced by treatment with the mTOR complex 1 (mTORC1) 
inhibitor rapamycin, suggesting that downstream of the insulin 
receptor mTORC1 mediates the effects of insulin on α cell mass 
and glucagon secretion (11, 12). The amino acids arginine, ala-
nine, and glutamine potentiate glucagon secretion and this effect 
is suppressed by high glucose in an insulin-independent manner 
(13). Recent studies demonstrate that interruption of glucagon 
receptor signaling by genetic inactivation or treatment with small 
molecules or glucagon receptor antibodies increases amino acid 
availability and leads to increased α cell proliferation in an mTOR-
dependent manner (12, 14–17). These findings support the concept 
that α cell mass and glucagon secretion are sensitive to extracellu-
lar signals including nutrients (amino acids, glucose) and growth 
factors (insulin) and that the mTORC1 pathway may be involved 
as a downstream regulator of one or both of these processes. How-
ever, how downstream targets of nutrient or insulin receptor sig-
naling regulate α cell mass and glucagon secretion in vivo is cur-
rently unknown.
To investigate the importance of endogenous mTORC1 func-
tion in α cell mass and glucagon secretion, we generated mice with 
tissue-specific deletion of Raptor in α cells. Our data uncovered 
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transcription of critical α cell genes. This work 
provides insights into how nutrient-dependent 
glucagon secretion and α cell mass are regulated 
and suggest that pharmacologic inhibition of this 
pathway using immunosuppressant medications, 
such as everolimus or rapamycin, could alter glu-
cagon levels and glucose homeostasis.
Results
Lack of mTORC1 signaling after deletion of Raptor 
in α cells. α Cell–specific deletion of Raptor was 
achieved by crossing glucagon-Cre and Raptorfl/fl 
mice (αRaptorKO) (18, 19). Deletion of flanked 
exon 6 exclusively in α cells from αRaptorKO mice 
was demonstrated by nested reverse transcrip-
tion PCR (RT-PCR) for exon 6 using different 
tissues and single α cells (Figure 1A) (19). Loss 
of mTORC1 signaling was confirmed by lack of 
phospho-S6 (Ser240) immunofluorescence stain-
ing only in glucagon-positive cells in dispersed 
islets from 1-month-old αRaptorKO mice (Figure 
1B). To validate the reduction in mTORC1 signal-
ing in α cells from αRaptorKO mice, we assessed 
phospho-S6 (Ser240), glucagon, and insulin 
staining in dispersed islets by flow cytometry 
using quantitative mean fluorescence intensity 
(MFI). Figure 1C shows pS6 MFI levels in α cells 
(glucagon+ cell count) and Figure 1D includes 
pS6 MFI levels in β cells (insulin+ cell count). 
Phospho-S6 (Ser240) levels were nearly lost in 
glucagon-positive cells from αRaptorKO mice (red 
curve) compared with controls (black curve) (Fig-
ures 1C). In contrast, the MFI for phospho-S6 
(Se240) was similar in insulin-positive cells from 
αRaptorKO mice (red curve) and controls (black 
curve) (Figure 1D). Recombination efficiency of 
glucagon-Cre assessed by crossing these mice to 
reporter mice showed that Cre-mediated recom-
bination was achieved in the majority of α cells 
(84.2% ± 6.4%, n = 4). We also report glucagon-
Cre recombination in neurons of the nucleus of 
the solitary tract (nucleus tractus solitarius, NTS) 
(Supplemental Figure 1; supplemental mate-
rial available online with this article; https://doi.
org/10.1172/JCI90004DS1).
Low fed and fasting glucagon levels in mice with 
loss of mTORC1 signaling in α cells. Body weight 
and random-fed blood glucose were not dif-
ferent between control mice and αRaptorKO or 
αRaptorHET (glucagon-Cre; Raptorfl/+) mice (Fig-
ure 2, A and B). Glucose tolerance at 2 and 8 months of age was 
not different between the 3 groups (Figure 2, C and G). Control 
mice exhibited a decrease in glucose levels after 12 hours of fast-
ing at both 2 and 8 months of age (Figure 2, D and H). In contrast, 
2-month-old αRaptorKO mice were able to maintain blood glu-
cose levels during the first 12 hours of fasting and glucose almost 
returned to the levels of control mice at 24 hours (Figure 2D and 
a potentially novel role of mTORC1 in maintenance of postnatal 
α cell mass and identified a previously unknown function of this 
pathway on glucagon secretion during fasting and hypoglycemia by 
modulation of KATP channel subunit expression (SUR1 and Kir6.2) 
and channel activity. We also discovered that mTORC1 positively 
regulates FoxA2 levels, a known regulator of SUR1, Kir6.2, and 
glucagon transcription, providing a link between mTORC1 and 
Figure 1. Loss of Raptor and mTORC1 activity in α cells of αRaptorKO mice. (A) Nested RT-
PCR amplification of Raptor exon 6 (flanked exon) in tissues and single α cells from control 
and αRaptorKO mice was performed as described in Methods. (B) Immunofluorescent stain-
ing for mTORC1 activity in α cells assessed by phospho-S6 (Ser240) and glucagon staining 
in dispersed islets from 1-month-old control and αRaptorKO mice. Scale bars: 10 μm. (C) 
Assessment of phospho-S6 (Ser240) staining by flow cytometry in glucagon-positive cells 
from young control and αRaptorKO mice (n = 3–4). (D) Flow cytometric analysis showing pre-
served mTORC1 activity by phospho-S6 (Ser240) in insulin-positive cells of young αRaptorKO 
mice (n = 3–4). MFI, mean fluorescence intensity.
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αRaptorKO and αRaptorHET mice (Figure 2, E and I). No differences 
were observed in fed or fasting insulin levels between controls, 
αRaptorKO, and αRaptorHET mice at 2 and 8 months (Figure 2, F and 
J). Finally, assessment of GLP-1 levels showed no difference in fed 
or fasting circulating active GLP-1 between αRaptorKO, αRaptorHET, 
and controls at 2 months of age (Supplemental Figure 3A). Active 
GLP-1 levels in intestinal extracts from 2-month-old mice showed 
no differences between control and αRaptorKO mice, suggesting 
that intestinal enteroendocrine cells expressing GLP-1 were con-
served, perhaps due to mosaic Cre-mediated recombination in 
intestinal stem cells (Supplemental Figure 3B).
mTORC1 signaling is necessary for the maintenance of postnatal 
α cells. Morphometric analysis at postnatal day 1 (newborn) dem-
onstrated that αRaptorKO mice were born with normal α cell mass 
(Figure 3, A and B, α cells depicted with white arrows). At 2 weeks 
of age, αRaptorKO mice exhibited normal α cell mass, lower levels 
of proliferation (assessed by Ki67), and no changes in apoptosis 
(assessed by TUNEL) (Figure 3C and Supplemental Figure 4, A 
and B). αRaptorKO mice displayed loss of α cells as evidenced by 
a reduction in α cell mass starting at 1 month of age (Figure 3, A 
and D; α cells depicted with white arrows in 3A). Flow cytometric 
Supplemental Figure 2A). αRaptorKO mice showed increased glu-
cose levels after intraperitoneal pyruvate injection, implying that 
increased gluconeogenesis could play a role in the resistance of 
αRaptorKO mice to a decrease in blood glucose during fasting (Sup-
plemental Figure 2B). Consistent with this, liver weight and glyco-
gen content decreased, but tended to be higher in αRaptorKO after 
overnight fasting (Supplemental Figure 2, C and D). The results of 
these studies suggest that αRaptorKO mice were more resistant to a 
decrease in glucose during the first 12 hours of fasting by increased 
gluconeogenic pathways, but these mechanisms were less effective 
after prolonged fasting (24 hours). Examination of glucose during 
fasting at 8 months of age showed a similar reduction in fasting 
glucose among all groups (Figure 2H). Assessment of glucagon in 
the fed and fasting states showed lower fed and fasting glucagon 
levels in αRaptorKO mice at 2 and 8 months of age (Figure 2, E and 
I). Interestingly, fed and fasted glucagon levels were also reduced 
in αRaptorHET mice at 2 and 8 months, but not to the level observed 
in the αRaptorKO mice (Figure 2, E and I). A trend towards increased 
glucagon levels was observed in 2- and 8-month-old control mice 
in response to fasting (Figure 2E). Compared with controls, glu-
cagon levels decreased after 12-hour fasting in young and old 
Figure 2. Mice with loss of mTORC1 signaling in α cells exhibit low fed 
and fasting glucagon levels. (A) Body weight and (B) random-fed blood 
glucose levels in control, αRaptorKO, and αRaptorHET mice (n = 9). (C) 
Intraperitoneal glucose tolerance test in 2-month-old (n = 3–4) and (G) 
8-month-old control, αRaptorKO, and αRaptorHET mice (n = 5–8). (D) Fasting 
blood glucose in 2-month-old (n = 7–9) and (H) 8-month-old (n = 3–4) con-
trol, αRaptorKO, and αRaptorHET mice. (E) Fed and fasted glucagon levels 
in 2-month-old (n = 5–6) and (I) 8-month-old (n = 5–6) control, αRaptorKO, 
and αRaptorHET mice. (F) Fed and fasted insulin levels in 2-month-old  
(n = 3–4) and (J) 8-month-old mice (n = 4). Data are shown as means ± 
SEM. *P ≤ 0.05 (1-way ANOVA with Dunnett’s post-test).
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mice suggested that these mice exhibited a defect in glucagon 
secretion. To further investigate the role of mTORC1 in glu-
cagon secretion, we subjected these mice to different stimula-
tory conditions in vivo. Examination of glucagon secretion by 
insulin-induced hypoglycemia in 2-month-old mice showed that 
insulin induced similar decreases in blood glucose in αRaptorKO, 
αRaptorHET, and control mice (Figure 4A). However, glucagon 
secretion after insulin-induced hypoglycemia was compromised 
in αRaptorKO mice and this was likely explained by the severe loss 
of α cell mass (Figure 4B). In contrast, αRaptorHET mice were able 
to respond, but showed reduced glucagon secretion at 30 minutes 
after insulin injection (Figure 4B). Next, we examined glucagon 
secretion under glucoprivic signals induced by 2-deoxy-D-glucose 
(2DG) injection, a nonmetabolizable glucose analog that inhib-
its phosphorylation of glucose by hexokinase (Figure 4C). 2DG 
administration raises blood glucose by increases in counterregu-
latory hormones (epinephrine, corticosterone, and glucagon) and 
hepatic glucose output. Assessment of glucagon secretion after 
2DG injection showed that αRaptorKO failed to respond to gluco-
privic conditions, a defect that was likely due to severe loss of α cell 
mass. (Figure 4D). αRaptorHET mice displayed impaired glucagon 
responses compared with the controls at 30 minutes after 2DG 
injection (Figure 4D). Interestingly, αRaptorHET mice had a higher 
response in blood glucose output at 30 minutes, suggesting that 
compensatory counterregulatory responses could be enhanced in 
conditions of chronic low glucagon (Figure 4D). These data further 
showed that αRaptorHET mice have a defect in glucagon secretion.
Rapamycin treatment in vivo inhibits glucagon secretory responses 
to hypoglycemia and reduces glucagon content in isolated islets. To vali-
date the alterations in glucagon secretion observed in αRaptorHET 
mice, we assessed the effect of pharmacologic inhibition of 
mTORC1 by intraperitoneal administration of rapamycin to wild-
type mice every other day for total of 5 injections (Figure 5A). Body 
weight and fed blood glucose were not affected by rapamycin or 
vehicle treatment (Figure 5, B and C). After insulin-induced hypo-
glycemia, rapamycin-treated mice displayed lower glucose at 120 
minutes after insulin injection, suggesting a decrease in counterreg-
ulatory responses to hypoglycemia (Figure 5D). Evaluation of the 
glucagon response in these mice revealed that glucagon secretory 
response to hypoglycemia was blunted (Figure 5E) and glucagon 
content in isolated islets was reduced in rapamycin-treated mice 
(Figure 5F). In order to avoid confounding factors that result from 
systemic actions of rapamycin, we measured glucagon secretion in 
wild-type islets after acute exposure to rapamycin. In these stud-
ies, wild-type islets were preincubated with 30 nM rapamycin for 
30 minutes followed by a 2-hour incubation with different glucose 
concentrations from 1 mM to 24 mM. As expected, glucagon secre-
tion decreased with higher glucose concentrations in untreated 
control islets (Figure 5G). However, 30 minutes of rapamycin treat-
ment decreased glucagon secretion at 1 mM glucose, confirming 
in vivo data showing that rapamycin inhibits glucagon secretion in 
response to hypoglycemia (Figure 5G). In addition, glucagon secre-
tion was suppressed by increasing glucose conditions and this effect 
was not altered by rapamycin. The reduction in glucagon secretion 
induced by acute treatment with rapamycin was not explained by 
alterations in glucagon content (Figure 5H), suggesting that short-
term rapamycin treatment can inhibit glucagon secretion induced 
analysis showed that the reduction of α cell mass at 1 month of age 
resulted from increased apoptosis (assessed by annexin V) and a 
trend towards decreased proliferation (assessed by Ki67) (Supple-
mental Figure 4, C and D). α Cell mass progressively decreased 
in αRaptorKO mice at 2 and 8 months (Figure 3, A, E, and G). A 
progressive decline in total pancreatic glucagon content was also 
observed at 2 and 8 months (Figure 3, F and H). In contrast, β, δ 
(somatostatin), and pancreatic polypeptide (PP) cell mass were 
not altered in 2-month-old αRaptorKO mice (Figure 3, I and J and 
Supplemental Figure 4, E–G). α Cell mass and pancreatic gluca-
gon content were comparable between controls and in αRaptorHET 
mice at 2 months of age (Figure 3, E and F). However, by 8 months 
αRaptorHET mice showed a reduction in α cell mass and pancreatic 
glucagon content (Figure 3, G and H). The number of α cells in 
older αRaptorHET mice assessed by flow cytometry was reduced, 
confirming these results (Supplemental Figure 4J). However, cell 
size and cellular glucagon content measured by flow cytometry 
was unaltered in the remaining α cells of αRaptorHET mice (Supple-
mental Figure 4, D and E). Electron microscopy in 1-month-old 
αRaptorKO showed a reduction in α cell size that was confirmed 
by cell size measurements (Figure 3, K and L). In addition, the 
number of glucagon granules appeared reduced in α cells from 
αRaptorKO mice and this was independently validated by reduced 
intracellular glucagon levels using flow cytometry (Figure 3M). 
Given the known role of mTORC1 in autophagy, we designed 
experiments to examine the contribution of autophagy to the 
loss of α cells in αRaptorKO mice by crossing to an in vivo reporter 
of autophagy (GFP-LC3 mice) (20). These studies showed that 
αRaptorKO exhibited increased GFP-LC3 puncta in α cells, consis-
tent with the presence of increased autophagy (Figure 3N). Taken 
together, the results of these studies suggest that reduction in α 
cell mass between 2 and 4 weeks results from a combination of 
decreased proliferation and increased apoptosis.
αRaptorHET mice have decreased glucagon responses to hypoglyce-
mia and glucoprivic conditions. The lower fasting glucagon levels 
with concomitant normal α cell mass in 2-month-old αRaptorHET 
Figure 3. mTORC1 signaling is necessary for maintenance of postnatal α 
cells. (A) Immunofluorescent staining for insulin and glucagon in pancre-
atic sections from control, αRaptorKO, and αRaptorHET mice (α cells depicted 
with white arrows). Scale bars: 50 μm. (B) Quantification of α cell fraction 
at postnatal day 1 (newborn) control, αRaptorKO, and αRaptorHET mice  
(n = 3). (C) Quantification of α cell mass at 2 weeks (n = 4), (D) in 1-month-
old (n = 4), and (E) 2-month-old control, αRaptorKO, and αRaptorHET mice 
(n = 4–5). (F) Pancreatic glucagon content (n = 4–6) in 2-month-old mice. 
(G) Quantification of α cell mass (n = 3–4) and (H) pancreatic glucagon 
content (n = 3–4) in 8-month-old mice. (I) Quantification of β cell fraction 
at postnatal day 1 (newborn) (n = 3) and (J) β cell mass in 2-month-old 
mice (n = 4–5). (K) Electron microscopy of α cells from 1-month-old control 
and αRaptorKO mice. Scale bars: 800 nm (control) and 600 nm (αRaptorKO). 
(L) Quantification of α cell size by morphometric analysis in control and 
αRaptorKO mice at 1 month of age (n = 3). (M) Analysis of glucagon content 
by flow cytometric analysis in dispersed α cells from control and αRaptorKO 
mice at 3 weeks of age (n = 3–4). MFI, mean fluorescence intensity. (N) 
Quantification of GFP-LC3 puncta and representative images of dispersed 
α cells from 3-week-old control and αRaptorKO mice (n = 50 cells) crossed to 
an in vivo reporter of autophagy (GFP-LC3 mice). Scale bars: 10 μm. Data 
for C, D, L, and N are shown as means ± SEM. *P ≤ 0.05 (Student’s 2-tailed 
t test). Data for B and E–J are shown as means ± SEM. *P ≤ 0.05 (1-way 
ANOVA with Dunnett’s post-test).
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by low glucose independently of alterations in glucagon content. 
Similarly, glutamine also failed to stimulate glucagon secretion in 
wild-type islets also treated acutely with rapamycin (30 nM), and 
these changes were independent of glucagon content (Supplemen-
tal Figure 5, A and B).
Glucagon secretory responses induced by pharmacologic manipu-
lation of KATP channels in αRaptorHET islets is abnormal. To uncover 
the mechanisms responsible for impaired glucagon secretion in 
αRaptorHET mice, we examined secretory responses of isolated 
islets. Glucagon secretion in response to depolarization induced 
by potassium chloride (KCl; 30 mM) was similar between control 
and αRaptorHET islets (Figure 6A). Next, we examined the glucagon 
response to arginine, a secretagogue that induces glucagon secre-
tion in part by modulating KATP channels (21). Glucagon secretion 
induced by arginine was blunted in αRaptorHET islets (Figure 6B). 
Taken together, these data suggested that the defect in glucagon 
secretion in αRaptorHET mice resided in steps prior to cell depo-
larization and possibly at the level of the KATP channel. We further 
evaluated glucagon secretion during pharmacological modulation 
of KATP channel activity with increasing concentrations of tolbuta-
mide (KATP channel antagonist) and diazoxide (KATP channel ago-
nist). Under low-glucose conditions, when a relatively larger frac-
tion of KATP channels are open, tolbutamide treatment of control 
islets induced glucagon secretion up to concentrations of 10 μM, 
whereas glucagon secretion was inhibited at higher concentra-
tions, as previously described (22–24). In contrast, tolbutamide 
treatment of αRaptorHET islets failed to induce glucagon secre-
tion and suppressed glucagon release at lower concentrations of 
tolbutamide (Figure 6C). Next we tested the effects of diazoxide- 
mediated opening of KATP channels at high glucose, where most 
KATP channels should be closed. Increasing concentrations of 
diazoxide (0–10 μM) relieved the suppression of glucagon secre-
tion in control islets (Figure 6D). In contrast, islets from αRaptorHET 
mice were unresponsive to diazoxide and this agent failed to 
induce glucagon secretion (Figure 6D). Conversely, under low-
glucose (1 mM) conditions when at least some KATP channels are 
open, diazoxide further induced glucagon secretion at 1 μM fol-
lowed by a dose-dependent suppression at 10 and 100 μM in con-
trol islets (Figure 6E). Under this condition, αRaptorHET islets still 
failed to respond to diazoxide (Figure 6, D and E). Taken together, 
these studies suggested that KATP channel function is altered in α 
cells with reduced mTORC1 signaling.
mTORC1 positively regulates glucagon secretion by modulating 
KATP channel expression. Next, we tested whether the changes in glu-
cagon secretion obtained by pharmacologic manipulation of KATP 
channels in αRaptorHET mice resulted from alterations in KATP chan-
nel activity. Whole-cell patch clamp was performed on α cells at 
low glucose from Glucagon-CretdTomato and αRaptorHET;tdTomato mice 
expressing a fluorescent reporter in α cells. Following establish-
ment of the whole-cell patch clamp, and subsequent washout of 
intracellular ATP, KATP channel current was significantly reduced in 
αRaptorHET α cells compared with controls (Figure 6, F and G). To 
test the hypothesis that these results could be explained by altera-
tions in KATP subunit expression, we measured the expression of 
KATP channels subunits Kir6.2 and sulfonylurea receptor subunit 
1 (SUR1) in α cells. We isolated an enriched population of α cells 
by FACS using dispersed islets from αRaptorHET and control mice 
crossed to Ins1-EGFP and CAG-tdTomato reporter mice (refer to 
Methods and Supplemental Figure 6). Our data showed that the 
enriched α cell population from αRaptorHET had decreased SUR1 
and Kir6.2 mRNA expression (Figure 6H). Supporting these find-
ings, single-cell mRNA expression for SUR1 in α cells also showed 
that young αRaptorKO;tdTomato mice had fewer α cells positive for 
SUR1 (Figure 6I). Unfortunately, we were unable to detect expres-
Figure 4. αRaptorHET mice exhibit decreased glu-
cagon responses to hypoglycemia and glucoprivic 
conditions. (A) Glucose levels after intraperito-
neal injection of insulin in 2-month-old control, 
αRaptorKO, and αRaptorHET mice (n = 5–6). (B) 
Glucagon levels measured in the same group of mice 
at 0 and 30 minutes after insulin injection (1 U/kg) 
(n = 5–6). (C) Blood glucose levels after intraperito-
neal injection of 2-deoxy-D-glucose (150 mg/kg) in 
2-month-old control, αRaptorKO, and αRaptorHET mice 
(n = 4–5). (D) Glucagon levels at 0 and 30 minutes 
after 2-deoxy-D-glucose in the same group of mice 
(n = 4). Data are shown as means ± SEM. *P ≤ 0.05 
(1-way ANOVA with Dunnett’s post-test).
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sion of Kir6.2 in single cells using this methodology. Lastly, we 
measured mRNA and protein in αTC-1 cells, a glucagon-expressing 
cell line, treated with rapamycin (30 nM) for 48 hours. These stud-
ies showed that inhibiting mTORC1 signaling leads to decreased 
KIR6.2 and SUR1 protein and mRNA levels (Figure 6, J and K). 
Overall, our data showed that mTORC1 positively regulates the 
expression of KATP channels in α cells and this could explain in part 
the decrease in KATP channel current in αRaptorHET α cells.
Single-cell mRNA expression in α cells from αRaptorKO mice reveals 
alterations in critical α cell genes. To validate the expression studies 
and further explore the mechanisms linking mTORC1 to regula-
tion of α cell function and mass, we assessed expression of critical 
α cell genes using the Fluidigm C1 platform for RNA expression 
of single pancreatic islet cells (refer to Supplemental Table 3 for 
the list of genes analyzed). We analyzed an enriched population of 
α cells by FACS using dispersed islets from 3-week-old αRaptorKO 
and control mice crossed to Ins1-EGFP and CAG-tdTomato reporter 
mice, and further sorted these cells based on viability. Single-cell 
gene analysis validated the decrease in SUR1 and Kir6.2 expres-
sion in α cells from young αRaptorKO and further showed reduced 
Gcg (glucagon) gene expression in these mice (Figure 7A and Table 
1). Autophagy-associated genes Ulk1 and Ulk2 were decreased in 
αRaptorKO, confirming a known role of this pathway in autophagy. 
Importantly, gene expression of key transcription factors involved 
in α cell development and maintenance, such as FoxA2, Neuro-
gen3, Gata4, MafB, Pou3f4, Notch1, Rbpj, and Nkx2.2, were lower 
in αRaptorKO compared with control α cells (Figure 7A and Table 
1). Decreased expression of Ccnb1 (cyclin B) and EIF4E suggests 
that these genes could be involved in the alteration of α cell pro-
liferation seen in αRaptorKO. Single-cell gene analysis also identi-
fied targets involved in exocytosis and glucagon secretion, such as 
SNAP25 (synaptosomal-associated protein 25), Cacna1s (L-type 
voltage-dependent calcium channel) and Chrm3 (muscarinic ace-
tylcholine M3 receptor). Endoplasmic reticulum stress–associated 
genes, XBP1 and Hsp90ab1, were also decreased in αRaptorKO. 
FoxA2, Nkx2.2, and Pou3f4 expression was also decreased in αTC-1 
cells treated with rapamycin (30 nM) for 48 hours, validating the 
results obtained by the single-cell analysis (Figure 7B).
The reduction in FoxA2 expression in α cells from αRaptorKO 
was particularly interesting, as FoxA2 has been shown to directly 
promote Gcg, SUR1, and Kir6.2 gene transcription in α cells (25–
29). Therefore, we hypothesized that mTORC1 positively modu-
lates glucagon and KATP channel expression through regulation of 
FoxA2 expression. Flow cytometric analysis confirmed that FoxA2 
protein levels were also reduced in α cells from young αRaptorKO 
mice (Figure 7, C and D). In addition, nuclear FoxA2 levels were 
decreased, as measured by the ratio of signal intensity of nuclear 
FoxA2 over 4′,6-diamidino-2-phenylindole (DAPI) in the α cells 
from young control and αRaptorKO mice (Figure 7, E and F).
Discussion
The current studies extend previous reports by uncovering poten-
tially novel insights into the regulation of glucagon secretion 
and α cell mass by mTORC1 signaling using mice with tissue-
specific deletion of Raptor in α cells. This work demonstrates that 
mTORC1 signaling positively regulates α cell–mass maintenance 
and glucagon secretion during fasting, hypoglycemia, and glu-
coprivic signals. Our data show that mTORC1 is dispensable for 
α cell development, but plays a role in the maintenance of α cells 
after weaning. Importantly, these experiments uncover a poten-
tially novel role of mTORC1 signaling in the regulation of gluca-
gon secretion by transcriptional regulation of KATP channel subunit 
expression. We also present a potentially novel role of mTORC1 
in controlling critical transcription factors in α cells and identi-
fied FoxA2 as a potentially novel mTORC1 target. More impor-
tantly, the decrease in glucagon secretion and glucagon content 
by lack of mTORC1 activity was recapitulated by administration 
of the clinically used immunosuppressant and mTORC1 inhibitor, 
rapamycin. Rapalogs (rapamycin analogs including everolimus) 
are FDA-approved drugs that suppress mTORC1 activity and are 
routinely used as immunosuppressants in transplantation and for 
the treatment of several malignancies including insulinomas. Our 
data suggest that these mechanisms could negatively regulate glu-
cagon levels in vivo and thus inhibit glucagon responses to hypo-
glycemia in patients taking these medications.
Morphologic studies showed that the decrease in glucagon 
levels observed in αRaptorKO mice resulted from a loss of α cells 
after weaning (Figure 3, B–D). Interestingly, no changes in β cell 
mass were observed in αRaptorKO mice, suggesting that α cell 
loss in αRaptorKO mice has minor contributions to β cell mainte-
nance during normal conditions. The α cell dynamics associated 
with loss of mTORC1 signaling are interesting and suggest that 
mTORC1 is dispensable for α cell developmental programs, but 
play critical roles during the suckling–weaning transition state 
Table 1. Fluidigm single-cell analysis of α cells from 3-week-old 
control and αRaptorKO mice
Gene Fold Change P value
Ulk2 –12.79 0.002431
SNAP25 –11.28 0.002376
Foxa2 –5.52 0.012191
Neurog3 –5.18 0.000242
Abcc8 (SUR1) –4.66 0.018140
Notch1 –4.46 0.001665
Gata4 –4.09 0.000713
XBP1 –4.04 0.048825
Chrm3 –3.84 0.000087
Mafb –3.75 0.007382
Pou3f4 –3.71 0.016007
Lamtor1 –3.56 0.000370
Nkx2-2 –3.14 0.000418
Ccnb1 –3.00 0.000003
Cacna1s –2.92 0.030182
Eif4e –2.88 0.000065
Rbpj –2.65 0.017525
Ulk1 –2.50 0.000574
Kcnj11 (Kir6.2) –2.29 0.016501
Hsp90ab1 –1.76 0.027254
AGcg –57.57 0.001473
Fluidigm single-cell analysis of α cells from 3-week-old control and αRaptorKO mice  
(n = 3–6 mice). Fold change and P value of differentially expressed genes identified in 
single cells (Student’s 2-tailed t test and AMAST analysis)
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life and suggest that mTORC1 is important for the transition from 
a developmental to a mature program in α cells and the nutrition 
shift associated with weaning.
The current studies show that the physiological role of α cell 
mTORC1 in the regulation of glucose homeostasis appears to be 
minor. In particular, hypoglucagonemia failed to decrease glucose 
levels after 12-hour fasting in αRaptorKO mice (Figure 2D). Similar 
abnormalities in adaptation to fasting have been reported in other 
mouse models of near-total α cell ablation and low circulating 
glucagon levels (18, 31). These results are in marked contrast with 
the reduction in fasting glucose in mice with pharmacological or 
genetic inhibition of the glucagon receptor signaling (Gcgr-null), 
suggesting that low levels of glucagon in αRaptorKO mice are suffi-
cient to mediate proper glucagon receptor signaling and maintain 
normoglycemia in the fasting state (15, 32). Interestingly, fasting 
blood glucose was higher in αRaptorKO mice than in control mice 
after 12 hours of fasting (Figure 2D). Higher gluconeogenesis, as 
shown by intraperitoneal pyruvate tolerance test, could contrib-
characterized by a nutritional shift from a fat-enriched mater-
nal milk nutrition to a carbohydrate-rich diet. These results also 
suggest that mTORC1 in α cells might be important for nutrient-
induced signals induced by a carbohydrate-rich diet after wean-
ing. These results are consistent with evidence demonstrating 
that the weaning period plays a critical role in β cell dynamics and 
function (30). Our morphological studies and analysis by flow 
cytometry during the first month of life suggest that α cell loss in 
αRaptorKO mice after weaning resulted from decreased prolifera-
tion and enhanced apoptosis (Supplemental Figure 4, A–D). The 
role of autophagy in the α cell loss observed in αRaptorKO mice is 
unclear and future studies using genetic models or inhibitors of 
autophagy could be designed to answer this question. In contrast 
to αRaptorKO mice, αRaptorHET mice also showed reduction in α 
cell mass only at 8 months, suggesting that long-term reduction 
of mTORC1 activity could have an impact on controlling α cell 
mass (Figure 3G). In summary, these studies showed that α cell 
dynamics are altered in αRaptorKO mice during the first month of 
Figure 5. Rapamycin treatment in 
vivo inhibits glucagon secretory 
responses to hypoglycemia and 
reduces glucagon content. (A) Experi-
mental design used for administra-
tion of rapamycin to 2-month-old 
wild-type (WT) male mice. Intraperi-
toneal administration of rapamycin 
(2 g/kg) or vehicle control was 
performed every other day for 9 days 
(arrows). ITT, insulin tolerance test. 
(B) Body weight and (C) fed glucose 
levels before rapamycin treatment 
and day 8 of rapamycin treatment 
of WT treated with vehicle and WT 
treated with rapamycin (n = 4–5). (D) 
Glucose levels after intraperitoneal 
injection of insulin (1 U/kg) in WT 
treated with vehicle and WT treated 
with rapamycin for 8 days  
(n = 4–5). (E) Glucagon levels at 0 and 
30 minutes after insulin injection in 
the same group of mice (n = 4–5). (F) 
Glucagon content in isolated islets 
from WT treated with vehicle and WT 
treated with rapamycin for 9 days  
(n = 4; presented as fold change from 
WT+Vehicle). (G) Glucagon secretion 
and (H) islet glucagon content from 
isolated WT islets treated ex vivo 
with (30 nM) or without rapamycin 
(n = 3–4 mice/treatment). Data for B 
and C are shown as means ± SEM.  
*P ≤ 0.05 (1-way ANOVA with Dun-
nett’s post-test). Data for D–H are 
shown as means ± SEM. *P ≤ 0.05 
(Student’s 2-tailed t test).
Downloaded from http://www.jci.org on November 8, 2017.   https://doi.org/10.1172/JCI90004
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
9jci.org
Figure 6. mTORC1 regulates glucagon secretion by 
alterations in KATP channel expression and activity. 
Glucagon response from isolated islets to (A) KCl (30 
mM) (n = 8 mice) and (B) arginine (ARG, 20 mM) (n = 8 
mice) under low-glucose (LG, 1 mM) Krebs buffer. Gluca-
gon response in isolated islets to increasing concentra-
tions of (C) tolbutamide (0–100 μM) under low-glucose 
conditions (n = 3–4 mice), (D) diazoxide (0–100 μM) 
under high-glucose (6 mM) conditions (n = 5–8 mice), 
and (E) diazoxide (0–100 μM) under low-glucose condi-
tions (n = 7–11 mice). (F) KATP channel activity during 
washout of intracellular ATP and (G) current amplitude 
quantification at 180 seconds in α cells from control 
and αRaptorHET mice (n = 30–41 cells from 3–4 mice). (H) 
RNA expression of SUR1 and Kir6.2 in FACS-enriched α 
cell population from control and αRaptorHET mice  
(n = 6). (I) Single-cell analysis of SUR1 expression 
frequency in α cells from 1-month-old control and 
αRaptorKO mice (n = 20–21 cells from 3–4 mice). (J) RNA 
expression (n = 7–8) and (K) protein levels of SUR1 and 
KIR6.2 from αTC-1 cells treated with vehicle or rapamy-
cin (30 nM) for 48 hours (n = 7). All secretion assays 
(A–E) represent results from 2–3 independent experi-
ments. Data are presented as fold change and shown as 
means ± SEM. *P ≤ 0.05 (Student’s 2-tailed t test).
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α cell mass at 2 months (Figure 2E and Figure 3E). Importantly, 
2-month-old αRaptorHET mice also showed impaired glucagon 
secretion induced by insulin-induced hypoglycemia and gluco-
privic conditions, suggesting that mTORC1 activity is important 
for glucagon secretion (Figure 2E and Figure 5, B and D). Ex vivo 
studies in isolated islets from αRaptorHET mice also support a role 
for mTORC1 inhibition in glucagon secretion (Figure 6, A–H). 
Finally, αRaptorKO and αRaptorHET mice showed reduced glucagon 
levels in response to fasting at 2 and 8 months of age (Figure 2, 
E and I). Although the mechanism for this finding is unclear, it is 
possible that this reflects defective glucagon secretion in response 
ute to explaining this finding. In addition, it is possible that there 
are compensatory increases in counterregulatory mechanisms, 
as demonstrated by responses to 2DG administration (Figure 4, 
C and D). In contrast to the lack of glucose abnormalities, glu-
cagon levels in αRaptorKO were decreased in the fed and fasting 
state (Figure 2, E and I). These changes could be explained by a 
marked reduction in α cell mass observed in αRaptorKO, although 
it is possible that concomitant abnormalities in glucagon secre-
tion can contribute (Figure 3, E and G). In contrast, αRaptorHET 
mice exhibited a reduction in circulating glucagon levels in the fed 
and fasting state and these changes were associated with normal 
Figure 7. mTORC1 regulates the expression of genes involved in glucagon synthesis and regulation of glucagon secretion. (A) Heatmap represents mean 
Ct of differentially expressed genes (P > 0.05) from Fluidigm single-cell analysis of α cells from 3-week-old control and αRaptorKO mice (n = 3–6 mice) and 
(B) RNA expression of α cell transcription factors in αTC-1 cells treated with vehicle or rapamycin (30 nM) for 48 hours (n = 4–8/group). (C) FoxA2 protein 
expression and (D) quantification analysis by mean fluorescence intensity (MFI) in glucagon-positive cells from young control and αRaptorKO mice (n = 3–4). 
(E) Immunofluorescence images representing FoxA2 (red), glucagon (green), and DAPI (blue) staining of isolated and dispersed islets from young control and 
αRaptorKO mice. Scale bars: 10 μm. (F) Quantification of the ratio of the signal intensity of nuclear FaxA2 over DAPI in dispersed α cells from young control 
and αRaptorKO mice (n = 4 mice). Data in A represent the mean Ct of differentially expressed genes (P > 0.05) in single cells by Student’s 2-tailed t test and 
†MAST analysis. Data in B, D, and F are presented as fold change from control and shown as means ± SEM. *P ≤ 0.05 (Student’s 2-tailed t test).
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(Figure 5, G and H). Finally, decreased expression of several genes 
involved in secretory machinery (SNAP25, Chrm3, Cacna1s) in 
αRaptorKO mice indicates that additional mechanisms could also 
be involved (Figure 7A and Table 1). Taken together, these results 
uncovered a previously unknown function of mTORC1 signal-
ing in controlling glucagon secretion by modulating KATP channel 
activity and expression of KATP channel subunits as well as genes of 
the secretory machinery.
Our data showed that inhibiting mTORC1 signaling in 
αRaptorKO mice and chronic rapamycin administration in vivo 
leads to decreased glucagon content and glucagon secretion. 
Single-cell gene expression analysis further showed that the 
decreased glucagon content resulted from reduced glucagon (Gcg) 
gene expression in αRaptorKO and key transcription factors impor-
tant for α cell development, maintenance, and glucagon synthe-
sis including FoxA2, Neoreg3, Gata4, MafB, Pou3f4, and Nkx2.2 
(Figure 7A and Table 1) (38–41). The changes in FoxA2 were par-
ticularly interesting, as this transcription factor has been shown to 
play a major role in regulating Gcg, SUR1, and Kir6.2 expression 
(25–29). FoxA2 protein levels and nuclear FoxA2 levels were also 
significantly reduced in α cells from young αRaptorKO mice (Fig-
ure 7, C–F). The decrease in FoxA2 gene transcription in αRaptorKO 
mice together with published data linking FoxA2 to Gcg, SUR1, and 
Kir6.2 transcription suggest that reduction in FoxA2 could be the 
link between mTORC1 and Gcg, SUR1, and Kir6.2 transcription 
in αRaptorKO mice. A decrease in the FoxA2 targets MafB, Pou3f4, 
and Nkx2.2, also supports the concept that FoxA2-dependent 
transcription was reduced in αRaptorKO mice (26). Overall, our 
data identified mTORC1 as a potentially novel regulator of FoxA2 
and suggest that this transcription factor links nutrient signaling to 
transcriptional regulation in α cells.
In summary, dysregulation of glucagon secretion plays a major 
pathogenic role in the development of hyperglycemia in T2D 
and failure to secrete glucagon in T1D or advanced T2D patients 
results in recurrent hypoglycemia. These studies provide poten-
tially novel insights into the molecular mechanisms and signal-
ing pathways regulating glucagon secretion and α cell mass. Our 
findings identify mTORC1 as a major signaling pathway control-
ling glucagon secretion under states of low glucose and identify 
a potentially novel mechanistic link between mTORC1/FoxA2 in 
transcriptional regulation in α cells. These alterations were reca-
pitulated by treatment with the immunosuppressant rapamycin, a 
known mTORC1 inhibitor used in the clinic. The findings obtained 
by rapamycin treatment could have major clinical implications in 
responses to hypoglycemia in posttransplant diabetics and per-
haps explain the defects in counterregulation of hypoglycemia in 
patients after islet transplantation under chronic immunosuppres-
sion by rapamycin analogs (42, 43).
Methods
Animals. Mice were housed in a pathogen-free environment and main-
tained on 12-hour light/dark cycle at the University of Michigan Brehm 
Center Animal Facility. The glucagon-Cre mice (gift from George K. 
Gittes at the University of Pittsburgh, Pittsburgh, Pennsylvania, USA), 
express Cre recombinase driven by the glucagon promoter (18). These 
mice were crossed with Raptorfl/fl (gift from Michael N. Hall and Markus 
A. Rüegg at the University of Basel, Basel, Switzerland) (19). We gen-
to the increase in circulating amino acids during the fasting state. 
Taken together, these studies are consistent with the concept that 
mTORC1 is required to maintain glucagon levels during fasting 
and in response to hypoglycemia. Interestingly, suppression of 
glucagon secretion in the fed state appears to not be regulated by 
the insulin/insulin receptor/mTORC1 axis.
The current studies demonstrate that reduction of mTORC1 
signaling reduces glucagon secretion. The similar glucagon secre-
tory responses to KCl treatment in controls and αRaptorHET islets 
suggested that the events distal to calcium influx are conserved 
and the secretory defect occurred prior to cell depolarization (Fig-
ure 6A) (21). In contrast, glucagon responses to arginine, gluta-
mine, or tolbutamide were impaired in αRaptorHET (Figure 6, B and 
C, and Supplemental Figure 5). While tolbutamide and arginine 
should also depolarize the α cell, KCl likely provided a much stron-
ger depolarization that supports the sustained activation of L-type 
Ca2+ channels, as opposed to the P/Q-type channels that appear to 
control glucagon secretion under more physiologic conditions (33, 
34). Based on these findings, together with impaired responses to 
low glucose observed in vivo, we hypothesized that the mechanis-
tic defect in the glucagon secretory pathways in αRaptorHET lied 
at the level of the KATP channel. Therefore, we assessed glucagon 
secretion to pharmacologic agents that open or close KATP channels 
in a dose-response manner (Figure 6, C–E) as described previously 
(23). The dose-response alterations to diazoxide and tolbutamide, 
KATP channel activity modulators, are consistent with reduced KATP 
channels and currents in αRaptorHET α cells (Figure 6, F and G). 
Titration of KATP channel activity can enhance action potential fir-
ing to the point at which voltage-gated Na+, Ca2+, and K+ channels 
undergo voltage-dependent inactivation (35–37) and thus suppress 
glucagon secretion (as seen with 100 μM tolbutamide in the con-
trols). The lower density of KATP currents in the αRaptorHET α cells 
is therefore consistent with the suppressive effect of tolbutamide 
on glucagon secretion occurring at low glucose concentrations, 
and the lack of effect of diazoxide. Interestingly, the increase in 
glucagon secretion by diazoxide in control islets is opposite to 
previously published data showing that a similar concentration 
of diazoxide inhibits, rather than stimulates glucagon secretion 
(33). The mechanisms for these differences are not completely 
clear but it is important to note that a fraction of KATP channels in α 
cells are open even at low glucose (23, 34). Therefore, it is still pos-
sible for diazoxide to open more KATP channels at low glucose and 
have stimulatory rather than suppressive effects, depending on 
the fraction of open KATP channels at culture medium conditions 
used with low glucose. Expression studies demonstrated that the 
decrease in KATP currents in αRaptorHET α cells resulted in part from 
lower Kir6.2 and SUR1 mRNA expression in αRaptorHET mice, indi-
cating that mTORC1 signaling controls transcription of KATP chan-
nel components (Figure 6, F–H). Reductions in SUR1 and Kir6.2 
mRNA expression were validated in single α cell expression analy-
sis in αRaptorKO (Figure 6I, Figure 7A, and Table 1) and reductions 
in SUR1 and KIR6.2 protein and mRNA levels were validated in 
αTC-1 cells treated with rapamycin (Figure 6, J and K). Glucagon 
secretion induced by different secretagogues was reduced by 
acute treatment of wild-type islets with rapamycin, suggesting that 
mTORC1 could also modulate glucagon secretion by controlling 
KATP channel activity, although the precise mechanism is unclear 
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total pancreatic section area for each mouse were averaged and multi-
plied by the pancreas weight.
Dispersed cell staining was performed by gently dispersing iso-
lated islets with trypsin-EDTA (0.25% trypsin, 1 mM EDTA). The 
cells were cytofuged using a StatSpin Cytofuge 2 (Beckman Coulter) 
on slides pre-coated with poly-L-lysine. The cells were immediately 
fixed with 3.7% formaldehyde for 20 minutes and incubated with Tris- 
buffered saline containing 0.1% Triton for 10 minutes at room temper-
ature. For FoxA2 staining, the cells were additionally permeabilized 
with cold methanol at 4°C for 10 minutes (after fixation with formalde-
hyde). Analysis of nuclear FoxA2 and DAPI signal intensity was done 
on 16-bit images acquired at ×40 magnification. FoxA2 and DAPI 
levels were determined my measuring pixel intensity using Adobe 
Photoshop (Adobe Systems). Assessment of cell death was measured 
by immunofluorescence-based apoptosis TUNEL assay (Millipore) in 
3–5 stained sections (5 μm) separated by 200 μm and costained for 
glucagon and DAPI. Assessment of cell proliferation was measured 
by staining and counting Ki67+/glucagon+ cells (Sigma-Aldrich) in 
3–5 stained sections (5 μm) separated by 200 μm and costained for 
glucagon and DAPI. Cell size was calculated by immunofluorescent 
staining of dispersed islets from 1-month-old mice for glucagon and 
DAPI and measuring the area of glucagon-positive cells using NIH 
ImageJ software (v1/49d available at http://rsb.info.nih.gov/ij/index.
html). Assessment of Cre-mediated recombination was measured by 
counting the number of glucagon+/reporter+ cells in dispersed islets 
from Glucagon-CreYFP and Glucagon-CretdTomato mice (2 months old). 
Assessment of autophagy was assessed in control and αRaptorKO mice 
bred to GFP-LC3 mice (20). Islets from 1-month-old ControlGFP-LC3 
and αRaptorKO;GFP-LC3 mice were isolated, dispersed, and cytofuged on 
slides and stained for glucagon, GFP, and DAPI. All antibodies used 
are summarized in Supplemental Table 1.
Flow cytometry. Islets were isolated and incubated overnight in 
RPMI containing 5 mM glucose. The islets were dispersed into a single- 
cell suspension and fixed with a BD Pharmingen Transcription Factor 
Phospho Buffer Set (BD Biosciences). The fixed cells were incubated 
with conjugated antibodies overnight, at 4°C and with gentle rotation. 
Dead cells were excluded by Ghost Dye Red 780 (Tonbo). Glucagon, 
insulin, FoxA2, LC3, Ki67, annexin V, and pS6 (Ser240) expression 
was analyzed by MFI (a measure of protein expression or posttransla-
tional modification) per glucagon-positive cell using a BD LSR II (BD 
Biosciences). The size of live glucagon-positive cells was analyzed by 
forward scatter area (FSC-A) and glucagon MFI. All antibodies used 
are summarized in Supplemental Table 1.
Fluorescence-activated cell sorting (FACS). Control (glucagon-
Cre) and αRaptorHET mice were crossed to reporter mice Ins1- 
EGFP and CAG-tdTomato. The islets from 2-month-old Glucagon-
CreIns1GFP;tdTomato and αRaptorHET;Ins1-EGFP;tdTomato were isolated and incu-
bated overnight in RPMI containing 5 mM glucose. The islets were 
dispersed into a single-cell suspension. Sorting was performed on 
a FACS Aria III (BD Biosciences) at the University of Michigan and 
Moflo Astrios EQ (Beckman Coulter) at the University of Miami. 
Dead cells were excluded with DAPI (Sigma-Aldrich) or Ghost Dye 
Red 780. Cells expressing CAG-tdTomato (glucagon and insulin) and 
cells expressing Ins1-EGFP (all insulin) were sorted in separate collec-
tion tubes, representing the Tomato gate and GFP gate, respectively. 
Hormone content in each gate was analyzed in 4 control animals by 
ELISAs for glucagon (Duoset, R&D Systems) and insulin (Alpco) and 
erated 3 experimental groups for all described experiments: con-
trols (Raptorfl/fl, Raptor fl/+, and glucagon-Cre), αRaptorKO (glucagon- 
Cre; Raptorfl/fl), and αRaptorHET (glucagon-Cre; Raptorfl/+). All ani-
mals were born in expected mendelian ratios and expected lifespans. 
Reporter transgenic animals CAG-tdTomato, Ins1-EGFP and CAG-YFP 
were purchased from The Jackson Laboratory. Reporter transgenic 
mice, GFP-LC3 (RBRC number RBRC00806) were obtained from 
RIKEN with the permission of the depositor (Noboru Mizushima, The 
University of Tokyo, Tokyo, Japan) (20). All metabolic (2 or 8 months) 
and ex vivo islet secretion (2 months) studies were performed with 
aged-matched male mice. Islet morphometric analysis utilized age-
matched cohorts with male and female mice.
Metabolic studies. Body weight and random blood glucose were 
monitored monthly for a total of 4 months. Fed (9 AM) and fasting (12 
hours; 9 PM) glucose, insulin, and glucagon levels were evaluated in 
2- and 8-month-old males. Blood was obtained from the tail vein and 
blood glucose was measured with an Accu-Chek blood glucose meter. 
Glucagon and insulin levels were measured with ELISAs (Mercodia 
[25 μl assay] and Alpco, respectively). Active GLP-1 levels in plasma 
and intestinal tissue were measured by STELLUX Chemi Ultrasen-
sitive Active GLP-1 ELISA (7-36) amide (25 μl assay with a sensitiv-
ity of < 0.1 pM). Intraperitoneal glucose tolerance test (IPGTT) (2 g/
kg), insulin tolerance test (ITT) (1 U/kg), and 2DG (150 mg/kg) were 
performed by intraperitoneal injections of respective agents in 4- to 
6-hour-fasted male mice (44). Hepatic glucose production was mea-
sured by intraperitoneal injection of pyruvate (2 g/kg) in 16-hour- 
fasted male mice.
Hormone content analysis in tissue extracts. To measure pancreatic 
glucagon content and intestinal active GLP-1 content, we dissected 
and measured the weight of the pancreas and total intestine (intestine 
was cleaned prior to processing). The tissues were homogenized in 
acid-ethanol (3 ml) and incubated with gentle rotation at 4°C for 72 
hours. The tissue homogenate was centrifuged and glucagon or active 
GLP-1 level was measured in the collected supernatant (R&D Systems 
Duoset Glucagon Elisa and STELLUX Chemi Ultrasensitive Active 
GLP-1 ELISA 7-36). The hormone content measure takes into account 
the tissue weight and the final volume of supernatant collected (hor-
mone concentration multiplied by tissue weight and divided by the 
volume of supernatant from tissue extract). Liver glycogen content 
was measured with a Glycogen Assay Kit (Sigma-Aldrich) following 
the manufacturer’s instructions.
Preparation and in vivo treatment with agents. Rapamycin (LC 
Laboratories) was dissolved in 100% ethanol and stored at –20°C. 
The stock solution was further diluted in an aqueous solution of 5.2% 
Tween 80 and 5.2% PEG 400 with a final concentration of ethanol 
of 2% (45, 46). Wild-type mice were injected with rapamycin (2 mg/
kg) every other day for 9 days. ITT was performed on day 8 between 
injections. Necropsy was performed on day 9 after the last injection.
Immunofluorescence and cell morphometry. Pancreata were fixed in 
3.7% formaldehyde, embedded in paraffin and sectioned (5 μm). Fluo-
rescence images were acquired using a microscope (Leica DM5500B) 
and a motorized stage using a camera (Leica DFC360FX) (Leica 
Microsystems). Cell mass was determined in 5 stained sections (5 
μm) separated by 200 μm as previously described (47, 48). The area of 
insulin, glucagon, somatostatin, and pancreatic polypeptide and the 
area of each section were quantified with Image Pro Software (version 
7; Media Cybernetics). The ratio of the 5 hormone-stained areas to the 
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systems), 0.5 μl RNAse inhibitor (10 Units; Applied Biosystems), and 
0.5 μl dithiothreitol (10 mM; DTT). Following snap freezing on dry ice, 
cell lysates were subjected to first-strand cDNA synthesis by using a 
High-Capacity Reverse Transcription cDNA Kit following the manu-
facturer’s directions (Applied Biosystems). Each cell was treated as 
separate reaction yielding a final volume of 20 μl. Reverse transcrip-
tion (RT) reactions were carried out for 60 minutes at 42°C, followed 
by incubation at 75°C for 15 minutes. All cells underwent quantitative 
PCR amplification for glucagon and 18S. Only confirmed glucagon-
positive cells were included in the analysis.
Single-cell nested RT-PCR for SUR1 and raptor. For SUR1, cDNA from 
single cells obtained as described above was subjected to a first round 
of RT-PCR using 8 μl of RT reaction, outside SUR1 primers (0.5 μM), 
MgCl2 (2 mM), dNTPs (0.4 mM), and 2 Units Platinium Taq (Invitro-
gen), in a total volume of 20 μl. The first RT-PCR was performed under 
the following conditions: 3 minutes at 94°C, 35 cycles (94°C for 30 sec-
onds, 58°C for 60 seconds, 72°C for 3 minutes), and final elongation at 
72°C for 7 minutes using a MasterCycler pro S (Eppendorf). The product 
of the reaction was used as template for a second round of PCR using 
1 μl of first-PCR product template and 19 μl of a mix containing Power 
SYBR Green PCR Mix (Applied Biosystems), inside primers and water, 
and was performed using StepOnePlus detection system (Applied Bio-
systems). The final product for SUR1 was visualized in an ethidium 
bromide–stained agarose gel (2%) by electrophoresis. The results were 
analyzed by the presence or absence of a positive band. Positive (whole 
islets) and negative (water) controls were used in every experiment. 
Primers were purchased from IDT. All primer sequences are available in 
Supplemental Table 2. Confirmation of Raptor deletion was performed 
by nested RT-PCR of exon 6 (flanked exon) using cDNA obtained from 
single cells as described above. The first round of amplification was per-
formed with outside primers (exon 5 and exon 7; Supplemental Table 2). 
The product of this reaction was used as a template for a second round 
of amplification using exon 6–specific primers (Supplemental Table 2). 
See complete unedited gels in the supplemental material.
Single-cell analysis by Fluidigm. Islets from 3-week-old con-
trol (Raptor f/fIns1-GFP;tdTomato and Ins1-GFP;tdTomato (n = 6) and 
αRaptorKO;Ins1-EGFP;tdTomato (n = 3) were isolated, dispersed, and sorted 
based on GFP (β cells), RFP (α cells), and viability to enrich an α cell 
population. The viability (87%–97%) and concentration (250–300 
cells/μl) of cells were measured using a Countess Automated Cell 
Counter and mixed with C1 Cell Suspension Reagent (Fluidigm) in 
a 3:2 ratio. The cells were captured into a small-sized (5–10 μm) or 
middle-sized (10–17 μm) integrated fluidic circuit (IFC) before under-
going cell lysis, reverse transcription, and cDNA amplification in the 
C1 Single-Cell Auto Prep instrument. Capture sites containing a single 
cell were identified by careful examination of the IFC using an Olym-
pus CK2 inverted microscope. Quantitative RT-PCR of 96 Delta iGene 
Assays was performed by BiomarkHD (Fluidigm) using pre-amplified 
cDNA from single cells, positive (bulk cell), and negative (no template) 
controls from each IFC capture. Glucagon+ cells were identified as sin-
gle cells with detectable levels of Gcg gene expression in the Biomark 
HD data (Control n = 10, αRaptorKO n = 19 cells). Delta Gene Assays 
were validated for single-cell gene expression analysis on a Biomark 
HD using mouse pancreatic total islet mRNA serially diluted over 12 
two-fold dilutions (512 pg to 0.25 pg) and 7 replicates.
Quantitative real-time PCR. For mRNA expression of αTC-1 and 
islets, total RNA was extracted using the RNeasy isolation kit (Qiagen). 
normalized to the number of cells sorted. The β cell content in different 
islet batches was consistently around 30% among the different FACS 
experiments (Supplemental Figure 4). Assessment of viability after 
sorting in young Glucagon-CreIns1GFP;tdTomato and αRaptorKO;Ins1-EGFP;tdTomato 
mice showed similar viability between control and αRaptorKO mice 
(87%–98% postsorting viability).
KATP channel activity. Islets from Glucagon-CretdTomato and 
αRaptorHET;tdTomato mice, expressing a fluorescent reporter in α cells, 
were dispersed to single cells and plated overnight on 35-mm dishes 
as described previously (49). Cells were patch-clamped in the whole-
cell voltage-clamp configuration in a heated bath at 32°C–35°C using a 
HEKA EPC10 amplifier and PatchMaster Software (Heka Electronik) 
and patch pipettes with resistances of 5–6 MOhm after fire polishing. 
Whole-cell currents of KATP channels were recorded in response to 
voltage steps going to −60 and −80 mV from a holding potential of −70 
mV. For the KATP current measurement, the bath solution contained 138 
mM NaCl, 5.6 mM KCl, 1.2 mM MgCl2, 2.6 mM CaCl2, 5 mM HEPES, 
and 1 mM glucose (pH 7.4). The pipette solution for these experiments 
contained 125 mM KCl, 30 mM KOH, 1 mM MgCl2, 10 mM EGTA, 5 
mM HEPES, 0.3 mM Mg-ATP, and 0.3 mM K-ADP (pH 7.15). Following 
the experiments, α cells were positively identified by immunostaining 
for glucagon (guinea pig anti-glucagon, 1:5,000; Linco), and appropri-
ate secondary antibody (Alexa Fluor 594 goat anti-guinea pig, 1:200; 
Invitrogen). Data were analyzed using FitMaster (Heka Electronik).
Islet studies. Islet isolation was accomplished by collagenase diges-
tion as described previously (47). Glucagon secretion ex vivo was 
assessed by static incubation using isolated islets. Briefly, after over-
night culture in RPMI containing 5 mM glucose, islets were precultured 
in Krebs-Ringer (KRBB) medium containing 6 mM glucose and 0.2% 
BSA for 1 hour. Groups of 15 islets/mouse were placed in 8-μm cell cul-
ture inserts (Millicell), preincubated in high-glucose (HG) KRBB (6 mM 
glucose) for 1–2 hours and incubated subsequently for 1 hour in each of 
the following conditions: low-glucose (LG) KRBB (1 mM glucose, with 
a brief wash with LG between HG KRBB and LG KRBB) and LG KRBB 
plus arginine (20 mM) or KCl (30 mM). Dose-response experiments 
measuring glucagon response to diazoxide and tolbutamide were per-
formed using a 30-minute exposure per condition. Glucagon response 
after acute rapamycin treatment was performed in wild-type islets incu-
bated with 30 nM rapamycin for 30 minutes under increasing glucose 
concentrations from 1 mM to 24 mM for a total duration of 2 hours under 
rapamycin treatment. Glucagon response to glutamine and rapamycin 
(30 nM) was performed after a 30-minute incubation in KRBB con-
taining 4 mM glucose and increasing glutamine concentrations (1, 
3, and 5 mM) every 30 minutes for a total duration of 2 hours under 
rapamycin treatment. Assessment of glucagon content in islets was 
performed by acid-ethanol extraction using 15 islets per condition. All 
assays represent results from 2–3 independent experiments. Secreted 
glucagon levels and islet glucagon content were measured using Gluca-
gon Duoset ELISA. All glucagon secretion data were normalized to the 
islet glucagon content and presented as fold change.
Single-cell RT-PCR. The following methods were adapted and 
modified from Liss et al. and Shiota et al. (21, 50). Red-fluorescent α 
cells from dispersed islets obtained from 1-month-old ControltdTomato 
and αRaptorKO;tdTomato were individually hand-picked under an inverted 
phase-contrast microscope (Leica DMI 3000B). Each cell was col-
lected with a pipette adjusted to 1.5 μl in individual tubes with 3.5 μl 
water and 5 μl of a mix containing 1 μl 10× RT Buffer (Applied Bio-
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(51). The Gcg gene was identified as significantly different between the 
groups using MAST analysis.
Study approval. All protocols were approved by the University of 
Michigan and the University of Miami Animal Care and Use Commit-
tees and were in accordance with NIH guidelines.
Author contributions
NB designed and performed the experiments, analyzed results and 
wrote the manuscript. EBM conceived and designed experiments, 
analyzed results, and wrote the manuscript. NB, XQD, JC, KC, JG, and 
MBR performed experiments and analyzed results. GKG, MAR, and 
MNH generated mice. PEM designed and performed KATP channel 
activity experiments, analyzed results, and contributed to the writ-
ing and discussion of the manuscript. DD, ACP, and all other authors 
contributed to discussion and reviewed/edited the manuscript.
Acknowledgments
The authors wish to acknowledge funding resources for this 
essential contribution to this work. E.B.M. is mainly supported 
by a MERIT award from the Veterans Administration. This work 
was supported in part by Merit Review Award IBX002728A from 
the U.S. Department of Veterans Affairs Biomedical Laboratory 
Research and Development Program. Additional funding includes 
NIH grants R01-DK073716 and DK084236. N.B. was supported 
by NIH grant T-32-GM007315 and a Rackham Merit Fellowship 
(University of Michigan). J.C. was supported by NIH grants T-32-
GM007315 and HD007505. The work in the A.C.P. group is sup-
ported by grants from the Juvenile Diabetes Research Foundation 
(JDRF) (grants 5-2011-379 and 2-SRA-2016-149), Department of 
Veterans Affairs (BX000666), the NIH (DK89572, DK104211, 
DK106755), and the Vanderbilt Diabetes Research and Training 
Center (DK020593). D.D. was supported by a Vanderbilt Molecu-
lar Endocrinology Training Program grant (5T32 DK07563) and 
a JDRF Postdoctoral Fellowship Award. We acknowledge support 
from the Morphology and Image Analysis Core, Metabolomics 
Core and Phenotyping Core from the Michigan Diabetes Research 
Center (MDRC) (P30 DK020572). We would like to acknowledge 
Oliver Umland at the Flow Cytometry Core Facility (Diabetes 
Research Institute; University of Miami) and Lesley De Armas and 
Li Pan (CFAR; University of Miami; NIH P30AI073961). We thank 
Charles Burant, Ken Inoki, John Williams, and Lei Yin (University 
of Michigan) for discussion of the data.
Address correspondence to: Ernesto Bernal-Mizrachi, Depart-
ment of Internal Medicine, Division of Endocrinology, Diabetes 
and Metabolism University of Miami, Miller School of Medicine 
and Miami VA Health Care System, Miami, Florida 33136, USA. 
Phone: 305.243.5631; Email: ebernalm@med.miami.edu.
Gene expression was assessed by quantitative real-time RT-PCR using 
Power SYBR Green PCR Mix (Applied Biosystems) on a StepOneP-
lus detection system (Applied Biosystems) with a standard protocol 
including a melting curve. Relative abundance for each transcript was 
calculated by a standard curve of cycle thresholds and normalized to 
18S (αTC-1) and β-actin (islets). Primers were purchased from IDT, with 
the exception of Arx1, MafB, and Nkx2.2, which were purchased from 
Operon. All primer sequences are available in Supplemental Table 2.
Cell culture studies. αTC-1 cells clone 6 were purchased from ATCC 
Cell Lines and maintained according to the company’s instructions. 
For rapamycin experiments, the cells were cultured in 12-well plates 
and incubated in complete media with vehicle control or rapamycin 
(30 nM) for 48 hours.
Western blotting. αTC-1 cells were collected and lysed in lysis buf-
fer (125 mM Tris, pH 7; 2% SDS, 1 mM DTT) containing phosphatase 
(Roche Diagnostics) and protease (Sigma-Aldrich) inhibitor cocktails. 
Cell lysates were boiled for 10 minutes, loaded, and electrophoresed 
in 12% SDS-PAGE and transferred to polyvinylidene fluoride mem-
branes. All antibodies used are listed in Supplemental Table 1. Images 
were acquired using a Western Bright Sirius kit (BioExpress). Band 
densitometry was performed by measuring pixel intensity using NIH 
ImageJ software and normalized to actin in the same membrane. 
Detection of SUR1 was accomplished using an anti-SUR1 antibody 
(gift from Show-Ling Shyng, Oregon Health & Science University, 
Portland, Oregon, USA). See complete unedited blots in the supple-
mental material.
Electron microscopy. Islets were isolated and fixed with 2% glutar-
aldehyde overnight at 4°C, dehydrated, and embedded in Epon by the 
Microscopy & Image Analysis Laboratory Core (MiCores, University 
of Michigan). Ultrathin sections were stained with uranyl acetate and 
lead citrate. Images were recorded digitally using an electron micro-
scope (JEM-1400 Plus).
Statistics. Assessment of the normality of the data by D’Agostino-
Pearson (omnibus K2) supported the use of parametric statistical 
tests. The statistical analysis for comparisons between 2 groups was 
performed by unpaired (2-tailed) Student’s t test. One-way ANOVA 
with post-hoc Dunnett’s multiple comparisons test was used for com-
parisons among 3 or more groups over several time points (GraphPad 
Prism). P values less than or equal to 0.05 were considered signifi-
cant. Analysis of Fluidigm single-cell data identified 55 gene assays 
(Supplemental Table 3) that qualified for statistical analysis by 2-tailed 
Student’s t test (≥3 data points/group). Principle component analysis 
(PCA) was performed using gene expression from 55 genes to evaluate 
whether the groups were separated distinctively. The heatmap repre-
sents the mean Ct of differentially expressed genes (P > 0.05; absolute 
fold change > 1.5) from 2-tailed Student’s t-test analysis. We applied 
a second method of statistical analysis to the data set using R-based 
MAST (model-based analysis of single-cell transcriptomics) package 
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